The startup has exclusively licensed an integration engine from the University of Miami to augment its VIPER platform and improve trial recruitment specifically in precision oncology.
PLX8394 is currently being studied in a Phase I/II trial of BRAF-mutated tumors, and Novellus plans to use its next-generation sequencing-based FACT assay to help further develop the drug.
Under this agreement, Bixink will be responsible for seeking regulatory approval for Nerlynx in South Korea, and Puma could receive payments of up to $6 million from drug sales.
The deal with AstraZeneca follows a licensing agreement signed earlier this year with Memorial Sloan Kettering Cancer Center also covering radionuclide PARP inhibitor IP.
The deal will accelerate delivery of high-quality, deidentified clinical databases to CancerLinQ, its oncologist subscribers, partners, and the broader cancer community.
